We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pall Corporation Acquires Molecular Diagnostics Manufacturer GeneSystems

By LabMedica International staff writers
Posted on 03 Oct 2008
Pall Corp. (East Hill, NY, USA), a global leader in filtration, separation, and purification, has purchased GeneSystems (Bruz, France), a privately held biotechnology company that has developed a unique, easy-to-use, and cost-effective molecular diagnostics platform.

The acquisition of GeneSystems with its patented approach to rapid microbiologic detection equipment and disposables expands Pall's total fluid management (TFM) capabilities in the US$1 billion biopharmaceuticals process monitoring market. The acquisition also presents Pall with new opportunities in its environmental, food, and beverage and water markets.

Process monitoring includes the analytic tests required during biopharmaceuticals manufacturing for environmental monitoring, in-process control testing, and finished product release testing. These tests are receiving increased regulatory scrutiny and support under initiatives such as process analytic technology (PAT).

Founded in 2000, GeneSystems quickly gained market recognition for its quantitative Legionella diagnostic platform. Since its first product arrived on the market in 2004, GeneSystems has developed systems for the rapid and precise diagnosis of a range of pathogens, including food safety testing focused on Escherichia coli. These systems employ advanced sample preparation methods and real-time polymerase chain reaction (PCR) technology to enable fast and high throughput along with high reproducibility analysis of multiple DNA targets. Real-time PCR detects small quantities of specific microorganisms and provides results within hours.

"We are excited by this acquisition and the increased opportunities it presents for our pharmaceutical, biotechnology, environmental monitoring, quality control, and diagnostics programs,” said Eric Krasnoff, Pall Corporation chairman and CEO. "Customers seek better tools for rapid testing and process monitoring. GeneSystems expands our ability to provide total fluid management to meet customer's raw materials, production, testing, and environmental requirements. GeneSystems' unique technologies complement Pall's markets and global reach.”

"It is wonderful to join Pall and have the opportunity to expand on a global scale the very significant customer advantages that our team has achieved, diligently and creatively, during the last few years,” said Darryl Spurling, CEO of GeneSystems.

Pall Corp. is a global leader in the rapidly growing field of filtration, separation, and purification. Pall is organized into two businesses: life sciences and industrial. These businesses provide products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation, and broad industrial markets. The company has extensive operations around worldwide.

Related Links:
Pall Corp
GeneSystems


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Specimen Radiography System
TrueView 200 Pro

Latest Industry News

QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests
03 Oct 2008  |   Industry

BD Biosciences & Diagnostic Solutions to Merge with Waters
03 Oct 2008  |   Industry

2025 COMPAMED Innovation Forum Highlights Pioneering Work in Cancer Diagnostics
03 Oct 2008  |   Industry



PURITAN MEDICAL